UK health tests sold to consumers lack evidence, study finds
Researchers assessed 50 vendors and found many claims for earlier diagnosis were unsubstantiated, with most not explaining limitations or harms.
By Giovanni Sapere
3 min read

A study published in BMJ Open assessed the websites of 50 commercial health test vendors in the UK. It found that many claims for earlier diagnosis and better outcomes were unsubstantiated, and that most vendors did not explain the tests' limitations. The global market for such tests is predicted to grow from $1.6 billion in 2023 to $3.2 billion by 2029.
Fifty vendors, tests from £6.99 to £14,000
The researchers identified a sample of 50 U.K. individuals, companies and clinics promoting health tests to healthy people online. The tests included blood tests such as full blood counts, liver function and genetic testing; urine, stool and saliva tests for urinary protein, gut microbiome and cortisol; physiological tests such as pulmonary function, grip strength and ECGs; medical imaging including chest X-rays, MRI and ultrasound; and physical examinations such as pelvic and breast exams. Prices ranged from £6.99 for a home kidney albumin urine test to £14,000 for a "Platinum Assessment" with multiple tests carried out in a clinic. Many health checks were sold in packages like "well woman premium assessment" or "executive MOT". The findings were published in BMJ Open and first reported by MedicalXpress.
Claims of earlier diagnosis without evidence
36 of the 50 vendors made claims for earlier diagnosis and better outcomes. 48 claimed better knowledge of health, 16 claimed longer life despite no evidence, and 25 offered reassurance. Most (70%) did not explain the limitations of testing or its potential harms. Only 15 mentioned downsides, 9 overdiagnosis or false positives, 8 underdiagnosis or false negatives, and 9 inaccuracy. Contrary to NHS advice, 12 vendors offered mammograms to normal-risk, symptomless women under 50. 45 offered lipid and HbA1c tests to well adults under 40. 31 offered follicle-stimulating hormone tests to all women over 45. 28 offered qFIT to adults under 50. 13 offered breast exams, 9 pelvic exams, and 14 testicular exams to people without symptoms.
Read also on The Patent: Colorectal cancer rates rise across the United States after two decades of decline
Photo: Kenny Leys / Unsplash
A market growing from $1.6 billion to $3.2 billion
The sector is predicted to increase globally from $1.6 billion in 2023 to $3.2 billion by 2029, so the researchers insist there is an urgent need for stronger regulatory protection for consumers. They point out that NHS primary care is already experiencing the impacts of follow-up of test results initiated by consumers rather than the NHS. The tests range from simple blood panels to imaging with medical devices such as MRI and ultrasound scanners. The researchers argue that innovation—and the patent and intellectual property questions around medical devices—in direct-to-consumer testing has outpaced regulation. They compare the sector with pharmaceutical products, which have far more safeguards around sales, advertising, promotion and regulation of providers. The regulation around tests is weaker, they conclude.
Citizens want help interpreting results
The researchers canvassed the views of a group of citizens brought together for the study. Their reasons for considering commercial tests included ease of access and hoping a purchase would assist NHS interactions. They also expressed the need for help with understanding test results, but several clinics offered this only on payment of an additional fee. 36 vendors were regulated by the Care Quality Commission, and 41 had doctors who either owned or worked with them. Nurses worked in 11 organizations, pharmacists in 3, and a health care assistant in 1. But there was little information on any of this on many websites. The researchers acknowledge that internet searches may have missed some tests, that the search was limited to the U.K., and that not all information given to customers may have been available online. For patent news on artificial intelligence, startup invention, inventor stories, robotics and space technology, see The Patent Magazine.
AI-assisted article



